Literature DB >> 33403061

Giant Cell Tumour Around Knee Managed by Curettage and Zoledronic Acid with Structural Support by Fibula Cortical Struts.

V Singaravadivelu1, V Kavinkumar1.   

Abstract

INTRODUCTION: Giant cell tumour (GCT) of the bone is a benign tumour with a high tendency to recur after surgery. This study aimed to analyse prospectively the rate of local recurrence following management of giant cell tumours by curettage, using intravenous zoledronic acid as an adjuvant, and fibular struts to support the empty cavity after curettage.
MATERIALS AND METHODS: This study was carried out in ten cases of biopsy-proven GCTs: five males and five females, in the age group between 18 and 39 years. All patients were given three doses of zoledronic acid, one pre-operative and two post-operative. Extended curettage was done three weeks after the pre-operative dose of zoledronate. The cavity was left empty in all the cases. Fibular struts were used to support the cavity from collapse. Patients were followed-up for post-operative local recurrence. The functional status of the patients was assessed during each visit using the Musculoskeletal Tumour Society (MSTS) score.
RESULTS: There were no recurrences at a follow-up of two years. All patients had a stable knee and were able to bear weight fully. The average knee flexion was 75º. The average MSTS score of the study was 92%.
CONCLUSION: Extended curettage using hydrogen peroxide, systemic zoledronic acid adjuvant and leaving the cavity empty without using cancellous bone graft did not lead to a recurrence of GCT. Non-vascularised fibular strut provided adequate support while the cavity left empty after curettage did not collapse and there was good knee function.
© 2020 Malaysian Orthopaedic Association (MOA). All Rights Reserved.

Entities:  

Keywords:  GCT; fibula strut; recurrence; zoledronic acid

Year:  2020        PMID: 33403061      PMCID: PMC7752021          DOI: 10.5704/MOJ.2011.008

Source DB:  PubMed          Journal:  Malays Orthop J        ISSN: 1985-2533


  22 in total

Review 1.  Giant cell tumor of bone.

Authors:  Robert E Turcotte
Journal:  Orthop Clin North Am       Date:  2006-01       Impact factor: 2.472

2.  Treatment of local recurrences of giant cell tumour in long bones after curettage and cementing. A Scandinavian Sarcoma Group study.

Authors:  F Vult von Steyern; H C F Bauer; C Trovik; A Kivioja; P Bergh; P Holmberg Jörgensen; G Follerås; A Rydholm
Journal:  J Bone Joint Surg Br       Date:  2006-04

3.  Does curettage without adjuvant therapy provide low recurrence rates in giant-cell tumors of bone?

Authors:  G H Prosser; K G Baloch; R M Tillman; S R Carter; R J Grimer
Journal:  Clin Orthop Relat Res       Date:  2005-06       Impact factor: 4.176

4.  Curettage and reconstruction by the sandwich technique for giant cell tumours around the knee.

Authors:  Balaji Saibaba; Devendra Kumar Chouhan; Vishal Kumar; Mandeep Singh Dhillon; Sreekanth Reddy Rajoli
Journal:  J Orthop Surg (Hong Kong)       Date:  2014-12       Impact factor: 1.118

5.  Local administration of zoledronic acid for giant cell tumor of bone.

Authors:  Toshihiko Nishisho; Naoyoshi Hanaoka; Ryo Miyagi; Toshinori Sakai; Shunichi Toki; Mitsuhiko Takahashi; Endo Kenji; Natsuo Yasui; Koichi Sairyo
Journal:  Orthopedics       Date:  2015-01       Impact factor: 1.390

6.  Phenol as an adjuvant in the control of local recurrence of benign neoplasms of bone treated by curettage.

Authors:  R Capanna; A Sudanese; N Baldini; M Campanacci
Journal:  Ital J Orthop Traumatol       Date:  1985-09

7.  Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study.

Authors:  Sant Chawla; Robert Henshaw; Leanne Seeger; Edwin Choy; Jean-Yves Blay; Stefano Ferrari; Judith Kroep; Robert Grimer; Peter Reichardt; Piotr Rutkowski; Scott Schuetze; Keith Skubitz; Arthur Staddon; David Thomas; Yi Qian; Ira Jacobs
Journal:  Lancet Oncol       Date:  2013-07-16       Impact factor: 41.316

8.  Bisphosphonates reduce local recurrence in extremity giant cell tumor of bone: a case-control study.

Authors:  Lung Fung Tse; Kwok Chuen Wong; Shekhar Madhukar Kumta; Lin Huang; Tsun Cheung Chow; James Francis Griffith
Journal:  Bone       Date:  2007-09-06       Impact factor: 4.398

9.  Weakness of extensor hallucis longus after removal of non-vascularised fibula as an autograft.

Authors:  V U Shingade; S M Jagtap; A B Ranade
Journal:  J Bone Joint Surg Br       Date:  2004-04

10.  Local control of giant cell tumors of the long bone after aggressive curettage with and without bone cement.

Authors:  Zhen-hua Gao; Jun-qiang Yin; Xian-biao Xie; Chang-ye Zou; Gang Huang; Jin Wang; Jing-nan Shen
Journal:  BMC Musculoskelet Disord       Date:  2014-10-02       Impact factor: 2.362

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.